2013年2月4日讯 /生物谷BIOON/ --近些年，Gilead公司一直在寻求与其他生物医药公司达成关于抗癌药物的协议。在最近两年，Gilead公司已经为此类协议支付了12亿美元其中包括了与YM BioSciences和Calistoga公司的协议。Gilead公司的主要领域集中在HIV领域，因此公司希望凭借这些协议来进入肿瘤领域这个广阔的市场。

公司高管John Milligan表示，肿瘤领域是一个正在获得重大研究突破的领域，或许将超过此前所有的医学进步。因此，公司时刻对该领域的进展保持密切注意。外界猜测Gilead公司下一步可能希望并购或合作的公司包括Ariad医药公司和Infinity医药公司，因为在2012年12月，Ariad治疗白血病新药Iclusig (ponatinib)获得FDA批准；而Infinity公司虽然没有治疗癌症的新药，但外界认为Gilead公司可借助该公司进行更大规模的交易。（生物谷Bioon.com）

详细英文报道：

Gilead Sciences ($GILD) waves an active trigger finger for acquisitions. After loading up on cancer drugs through a number of deals in recent years, the biopharma powerhouse is looking for new targets, Bloomberg reported. And Gilead\'s interest in blood-cancer drugs sparked some speculation about a couple of likely buyout prospects.

As the news service reported, Gilead has ponied up $1.2 billion in two years to pick up cancer drugs. All those deals involved development-stage candidates from the buyouts of such firms as YM BioSciences and Calistoga Pharmaceuticals. Gilead, which has no marketed cancer drugs and makes most of its revenue from HIV meds, has invested heavily in research of cancer drugs in search of a future revenue stream from the big oncology market.

\"Oncology is entering an era where significant advances are going to be made, far above and beyond what\'s been made previously,\" John Milligan, Gilead\'s operations chief, told Bloomberg. \"It\'s a field where there\'s always the possibility of acquiring other molecules and companies as their technology or pipelines mature. We\'re certainly keeping our eye on it.\"

What cancer drug outfit might Gilead look to buy next? Milligan wouldn\'t say, of course. But Raghuram Selvaraju of Aegis Capital took a shot, saying that possible targets could include Ariad Pharmaceuticals ($ARIA) and Infinity Pharmaceuticals ($INFI). In December Ariad won FDA approval for Iclusig (ponatinib) for certain cases of chronic myeloid leukemia, and boasts a market cap of $3.34 billion that reflects the big expectations for the drug.

With no approved drugs, Infinity might be more akin to previous companies that Gilead scooped up. It\'s all just speculation right now, however.

Yet Gilead has the deep pockets and the track record in HIV to compete in the market for blood cancer drugs. And the Foster City, CA-based company could certainly pull the trigger on more sizable oncology buyouts.